Gadoterate meglumine is a paramagnetic contrast agent used in magnetic resonance imaging (MRI) procedures.
It is a chelate of the rare earth metal gadolinium and the organic ligand meglumine.
Gadoterate meglumine enhances the visualization of internal body structures by increasing the contrast between different tissues.
It is commonly used to detect and evaluate a variety of conditions, including brain and spinal cord lesions, tumors, and vascular abnormalities.
Experieince the power of optimized research protocols with PubCompare.ai's AI-driven platform, which can help you locate and compare the best protocols from literature, preprints, and patents to improve the reproducibility and accuracy of your Gadoterate meglumine research.
Most cited protocols related to «Gadoterate meglumine»
All CMR examinations were performed with subjects in a supine position on a 1.5 MR Tesla (Siemens Avanto, Erlangen, Germany) with a 32-element phased-array coil. During the last minute of adenosine infusion a gadolinium-based contrast agent (Gadodiamide, Omniscan®, GE Healthcare or Gadoterate meglumine, Dotarem®, Guerbet S.A.) was administered intravenously at 0.075 mmol/kg body weight (injection rate 4 ml/s), followed by a 20 ml saline flush at the same rate. Perfusion imaging was performed every cardiac cycle during the first pass, using a T1-weighted fast (spoiled) gradient echo sequence (echo time 1.05 ms, repetition time 2 ms, saturation recovery time 100 ms, voxel size 2.3 × 2.8 × 10 mm; flip angle 12°). Three or four short-axis slices, positioned from the base to the apex of the left ventricle, were obtained. The same imaging sequence was repeated at least 10 minutes later without adenosine to obtain perfusion images at rest. For assessment of left ventricular function, steady-state free-precession cine images (TE/TR 1.1/2.6 ms, voxel size 2.0 × 2.0 × 7 mm, flip angle 55°) were acquired in three long-axis views, and a short-axis stack to obtain coverage of the entire left ventricle. Analysis of left ventricular function was performed with Argus Syngo MR software (version B15, Siemens Healthcare, Erlangen, Germany) using the short-axis SSFP images as previously described [7 (link)]. The following left ventricular parameters were thereby determined: end-diastolic volume, end-systolic volume, ejection fraction and myocardial mass.
Karamitsos T.D., Ntusi N.A., Francis J.M., Holloway C.J., Myerson S.G, & Neubauer S. (2010). Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 12(1), 66.
The sequence was simulated by Bloch equations to calculate the transverse magnetization as a function of all the protocol and tissue parameters in order to construct the LUT corrections for both the AIF and myocardial imaging protocols. Input to the LUT was the normalized signal SR/PD, where PD used the FLASH protocol and SR used either a b-SSFP or FLASH protocol. LUT were validated by phantom measurement by comparing the estimates of [Gd] after LUT correction with the known [Gd] using least squares fitting. A set of gadolinium doped saline phantoms were constructed at concentrations up to 10 mmol/L using both Gadoterate meglumine (Dotarem, Guerbet LLC) and Gadobutrol (Gadavist, Bayer Healthcare). LUT estimates of [Gd] vs known [Gd] were calculated with and without T2* correction. The phantom T1 values were measured using an inversion recovery GRE sequence at multiple inversion times (TI) with TR = 10s such that the longitudinal magnetization was fully relaxed after each RF excitation, and T1 was estimated by 3-parameter fitting to the mono-exponential inversion recovery S = A-Bexp(-TI/T1). The phantom T2 values were measured using a spin echo sequence (TR = 10s) with varying echo times (TE) and using T2 estimates from a 2-parameter fit to the mono-exponential decay curve, S = Aexp(-TE/T2). The coefficients for relaxivity rates (r1 and r2) were calculated from the T1 and T2 measurements vs known [Gd] using linear fitting, i.e., R1 = R10 + r1[Gd] with R1 = 1/T1.
Kellman P., Hansen M.S., Nielles-Vallespin S., Nickander J., Themudo R., Ugander M, & Xue H. (2017). Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. Journal of Cardiovascular Magnetic Resonance, 19, 43.
Fontana M., White S.K., Banypersad S.M., Sado D.M., Maestrini V., Flett A.S., Piechnik S.K., Neubauer S., Roberts N, & Moon J.C. (2012). Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. Journal of Cardiovascular Magnetic Resonance, 14(1), 88.
Sixty rats were randomly divided into a control and 5 GBCA groups (n = 10 per group). The animals received the linear GBCAs gadodiamide (Omniscan; GE Healthcare Buchler GmbH & Co KG, Braunschweig, Germany), gadopentetate dimeglumine (Magnevist; Bayer Vital GmbH, Leverkusen, Germany), gadobenate dimeglumine (Multihance; Bracco Imaging Deutschland GmbH, Konstanz, Germany), or the macrocyclic GBCAs gadobutrol (Gadovist; Bayer Vital GmbH) and gadoterate meglumine (Dotarem; Guerbet GmbH, Sulzbach/Taunus, Germany) or saline (control). Over a period of 2 weeks, the animals received 10 intravenous injections at a dose of 2.5 mmol Gd/kg body weight (b.w.), each on 5 consecutive days per week. All investigated GBCAs were applied by slow hand injection (∼0.8 mL/min) using their marketed formulation. The extended dose of 2.5 mmol Gd/kg b.w. per injection approximates about 4 times the human standard dose based upon body surface area normalization between rats and humans.21 One day before the first GBCA administration, as well as 3 days after the last injection (p.i.), a whole-brain MRI was performed for all animals. Subsequently, 5 randomly chosen animals per group were euthanized by exsanguination for dissection. The other 5 animals per group received a second brain MRI before dissection at 24 days p.i. All tissue samples were frozen for further detailed analysis (ongoing). An overview of the study setup is shown in Figure 1A.
Jost G., Lenhard D.C., Sieber M.A., Lohrke J., Frenzel T, & Pietsch H. (2016). Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents. Investigative Radiology, 51(2), 83-89.
Forty-two patients with the diagnosis of primary UM were evaluated. The first cohort consisted of thirty consecutive patients, who were prospectively evaluated at the Leiden University Medical Center (LUMC), as part of a single-institution prospective study, carried out according to the Declaration of Helsinki. Following approval of the protocol by the local Medical Ethical Committee (METC P16.186), informed consent was obtained from all participants. The second group consisted of twelve patients, whose eyes were scanned for a clinical reason and that were retrospectively evaluated, with permission from the local Medical Ethical Committee. This group included one case treated with ruthenium brachytherapy, four cases that received proton beam therapy, and seven cases that underwent enucleation. All 42 patients were examined by an ocular oncologist, and the final diagnosis was made on the basis of fundoscopic, fluorescein angiographic, and ultrasonographic findings, prior to the MRI examination. The mean age of all subjects was 62 years (range 24–90) and 69% were male. In 61% of the patients, the lesion was localized in the right eye. The clinical American Joint Committee of Cancer T-Stage of the UM was T1 in 29%, T2 in 31%, T3 in 31%, and T4 in 9%. Regarding treatment, 45% of the cases received ruthenium brachytherapy, 21% proton beam therapy, and 33% were enucleated. In one patient, the diagnosis was not clear, and, prior to the MRI, a biopsy was performed, disclosing a UM. In all 14 patients who underwent enucleation histopathology confirmed the clinical diagnosis of UM (Supplementary Table 1). All patients underwent a 3T MRI (wide bore Ingenia 3T, Philips Healthcare, Best, The Netherlands), using the ocular protocol that we previously developed [8 (link)], with minor adjustments: a higher resolution of the 3D TSE T1 sequences, diffusion weighted imaging (DWI) with B values only of 0 and 800 s/mm2, and a higher flip angle of the dynamic scan (Table 1; Figure 1).
MRI scans’ parameters including both anatomical and functional sequences. The MS and DWI sequences are acquired perpendicular to the main axis of the tumor. The 3D TSE and DCE sequences are acquired on the axial plane non-angulated. During the DCE scan, intravenous administration of 0.1 mmol/kg gadoterate meglumine (gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex, France) is administered and afterwards, the contrast-enhanced (Gd) scans are acquired
Purpose
Scan name
Voxel size (mm3)
Echo train length
TE(ms)/TR(ms)/Flip or ref. angle (deg)
Fat supr.
Scan time (mm:ss)
Additional parameters
3D measurements
3D TSE T1
0.8×0.8×0.8
20
26/400/90
-
02:07
3D TSE T1 SPIR
0.8×0.8×0.8
20
26/400/90
SPIR
02:07
3D TSE T2 SPIR
0.8×0.8×0.8
117
305/2500/35
SPIR
02:58
3D TSE T1 SPIR Gd
0.8×0.8×0.8
20
26/400/90
SPIR
02:07
Tumor origin and extension
MS TSE T1
0.5×0.5×2.0
6
8/718/180
-
01:16
MS TSE T2
0.4×0.4×2.0
17
90/1331/120
-
01:25
MS TSE T1 SPIR Gd
0.5×0.5×2.0
6
80/764/180
SPIR
01:16
Functional scans
DWI (TSE)
1.25×1.4×2.4
Single shot
50/1555/50
SPIR
01:33
B=0.800 s/mm2
DCE
1.25×1.5×1.5
2.3/4.5/13
Proset 11
04:20
2 s/dynamic
MRI ocular protocol. Uveal melanoma of the left eye (white arrow) with associated retinal detachment (green arrow). ADC of 1.4 × 10−3 mm2/s. Wash-out time-intensity curve at DCE. A MS T1. B MS T2. C MS contrast-enhanced T1 with fat signal suppression. D 3D TSE T1. E 3D TSE T1 with fat signal suppression. F 3D TSE T2 with fat signal suppression. G 3D TSE contrast-enhanced T1 with fat signal suppression. H ADC. I Quantitative evaluation of the DCE. Black line—arrival time (T0) = timepoint at which the lesion starts to enhance, determined manually. Blue line—corresponds approximately to the peak time (T1) = first timepoint when the lesion reached 95% of its maximum intensity, determined automatically and corresponding to the timepoint at which peak intensity (PI) is calculated. Time to peak (TTP) (s) = T1-T0. Green line—outflow percentage at 2 min (OP2,%) = percentage of signal intensity loss at 2 min compared to the intensity at the peak time. Notice the wash-out time-intensity curve. SI, signal intensity at every timepoint. SI0, signal intensity at timepoint zero
Tumor origin (choroid, ciliary body, or iris) was assessed on MRI. The presence of a mushroom configuration was evaluated on MRI; when histopathology was available, it was correlated with rupture of Bruch’s membrane. The signal intensity of UM on MRI was assessed and it was evaluated whether it reflects UM pigmentation, by comparing it both to fundoscopy and histopathology. Tumor signal intensity on T1- and T2-WI was classified as hyper-, iso-, or hypointense. When UM were compared to the vitreous on MRI, all were hyperintense on T1- and hypointense on T2-WI, showing the vitreous to be an unsuitable reference for their signal intensity. Better differentiation of signal intensities was obtained when using the signal intensity of the choroid as reference on T1- and of the eye muscles on T2-WI. Tumor pigmentation on fundoscopy was categorized as pigmented or non-pigmented. Tumor pigmentation on histopathology was classified according to their macroscopic color as seen in several cuts through the UM: white, no pigmentation; yellow/gray, slight pigmentation; brown, moderate pigmentation; black, strong pigmentation. We compared UM signal intensity on T1- and T2-WI and clinical pigmentation as seen on fundoscopy in the group of homogeneous or minimally heterogeneous UM (n=36). The six bipartite UM were excluded in this evaluation. We furthermore compared UM signal intensity on T1- and T2-WI with pigmentation on histopathology in the group of the 14 enucleated eyes. On the four enucleated eyes with bipartite UM, both components were separately checked, accounting for a total of 18 evaluable lesions. For the ADC measurements, one representative region of interest (ROI) was drawn by the same neuroradiologist, excluding the tumor edge and potential necrotic parts, and one reference ROI was drawn in the vitreous. The tumor perfusion characteristics—arrival time (T0) (s), time to peak (TTP) (s), peak intensity (PI), outflow percentage at 2 min (OP2,%), and the type of time-intensity curve (TIC)—were evaluated in 3D, all results corresponding therefore to the average from the whole UM. Additionally, the type of TIC was also evaluated in 2D: in homogeneous tumors from a representative 2D image, and in bipartite tumors from both tumor components. The type of TIC was classified according to Yuan et al. as persistent, plateau, or wash-out pattern [14 ]. However, to limit the effect of potential eye movement, the outflow was evaluated at 2 min, instead of the 5 min, being the plateau and wash-out patterns defined as a final intensity at 2 min of 95–100% and below 95% of the peak intensity, respectively (Figure 1) [14 ]. Tumor dimensions and tumor extension were evaluated on MRI and US and validated with histopathology when available. The presence of retinal detachment (RD) was evaluated with MRI and US. Finally, on the enucleated eyes, the presence of extracellular matrix patterns (defined as three adjacent full loops) and of monosomy 3 in the tumor was checked (Supplementary Table 2).
Ferreira T.A., Jaarsma-Coes M.G., Marinkovic M., Verbist B., Verdijk R.M., Jager M.J., Luyten G.P, & Beenakker J.W. (2021). MR imaging characteristics of uveal melanoma with histopathological validation. Neuroradiology, 64(1), 171-184.
Six healthy female New Zealand rabbits (3.2 ± 0.4 kg) (Charles River, France) were used to compare the signalto-noise ratio (SNR) in the abdominal aorta (AA) of gadopiclenol (Elucirem, Guerbet, batch 19 M003) and gadoterate meglumine (Dotarem, Guerbet, batch 20GD020A01) from the first pass to 10 minutes after injection. A total of 4 doses of gadopiclenol (0.025, 0.05, 0.075, and 0.1 mmol Gd/kg) and 1 dose of gadoterate meglumine (0.1 mmol Gd/kg) were evaluated. Each rabbit received 5 injections with an interval of at least 5 hours between injections to ensure complete washout. During the procedure, the rabbits were kept under gas anesthesia (induction at 4%, injection at 3%; IsoFlo, Axience, Pantin, France). Contrast agents were injected through the marginal ear vein, with a total injection volume of 2 mL composed of ([gadopiclenol or gadoterate meglumine dose + saline up to 1 mL] + [1 mL physiological serum = flush]). The injection rate was 0.25 mL/s (automatic injector, PHD 2000, Harvard Apparatus), corresponding to 2 mL/s in humans (cardiac output ratio equal to 8 between rabbits and humans 15-17 ) (Fig. 1A).
Hugon G., Adriaensen H., Wintrebert M., Arnould L., Serfaty J.M, & Robert P. (2024). Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs. Investigative radiology, 59(9).
Experimental setup for contrast-enhanced magnetic resonance angiography. A, Over 3 days, 6 healthy New Zealand female rabbits received 4 doses of gadopiclenol (0.025, 0.05, 0.075, and 0.1 mmol Gd/kg) and 1 dose of gadoterate meglumine (0.1 mmol Gd/kg). A minimum interval of 5 hours was fixed between 2 injections to allow for elimination of the CA/dose from the previous injection. At each dose, MRI was performed before injection and for 6 time points after injection (synchronized with the beginning of the injection, at 25, 50, 180, 300, and 600 seconds). B, Six healthy female farm pigs received 2 doses of CAs 1 week apart: a half gadolinium dose for gadopiclenol (0.05 mmol Gd/kg) and a full gadolinium dose for gadoterate meglumine (0.1 mmol Gd/kg). At each dose, MRI was performed before injection and a Care Bolus sequence was used to determine the arrival of CA in the aorta to initiate the 3D MRA sequence.
Hugon G., Adriaensen H., Wintrebert M., Arnould L., Serfaty J.M, & Robert P. (2024). Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs. Investigative radiology, 59(9).
Six healthy female pigs (45 ± 3 kg) (Unité Expérimentale de Physiologie Animale de l'Orfrasière, INRAE) were used for the in vivo MRA study to compare the first-pass SNR in the aorta between gadopiclenol at 0.05 mmol Gd/kg (Elucirem, Guerbet, batch 19 M003) and gadoterate meglumine at 0.1 mmol Gd/kg (Dotarem, Guerbet, batch 20GD020A01). The pigs received an intramuscular injection of 15 mg/kg ketamine (Imalgène 1000) and 2 mg/kg xylazine (Rompun 2%), followed by intubation. All GBCAs injections were performed under general anesthesia (isoflurane 3%/O 2 ). The pigs received 2 injections (gadopiclenol and gadoterate) with a 1-week interval between to ensure complete elimination of the first injection, in a randomized order. The CAs were injected through the ear vein, with a total injection volume of 0.1 mL/kg for gadopiclenol and 0.2 mL/kg for gadoterate, followed by 20 mL of saline flush. The injection rate was 2 mL/s for both CA and flush (using the automatic injector MEDRAD Spectris Solaris EP) (Fig. 1B), as applied by Endler et al. 10 For a 26-second temporal resolution sequence, the injection durations of ~2 seconds (gadopiclenol) and ~4 seconds (gadoterate) were considered as not that much different.
Hugon G., Adriaensen H., Wintrebert M., Arnould L., Serfaty J.M, & Robert P. (2024). Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs. Investigative radiology, 59(9).
MR imaging data included axial T2‐weighted imaging (T2WI), T1‐weighted imaging (T1WI), contrast‐enhanced T1WI (CE‐T1WI), and fluid‐attenuated inversion recovery (FLAIR) sequences obtained on 1.5T MRI system (GE, Octane; Siemens, Altea) and 3.0T MRI system (Philips, Achieva; GE, Premier). Post‐contrast T1WI were taken following intravenous injection of gadoterate meglumine through the median cubital vein at a flow rate of 2 mL/s (0.2 mL/kg body weight). The MRI parameters are provided in Supplementary 1.
Li Y., Chen L., Huang L., Li X., Huang Q., Tang L., Huang Z., Zhu L, & Li T. (2024). A radiomics‐based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma. Brain and Behavior, 14(5), e3528.
MRI for inner ear EH was performed on a 3-Tesla Siemens Magnetom ® Skyra scanner with a 64-channel head coil. MRI was performed 4 h after the intravenous administration of gadoterate meglumine (0.2 mmol/kg) with an isotropic (0.7 mm voxel) high-resolution three-dimensional inversion recovery (IR) sequence with real reconstruction. An additional T2-weighted sampling perfection with application-optimised contrasts using different flip angle evolution (SPACE) sequences was performed. Siemens product sequences were used with parameters as set out in Table 2.
Connor S., Pai I., Touska P., McElroy S., Ourselin S, & Hajnal J.V. (2024). Assessing the optimal MRI descriptors to diagnose Ménière's disease and the added value of analysing the vestibular aqueduct. European radiology, 34(9).
Sourced in France, Germany, United States, United Kingdom, Italy
Dotarem is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures during MRI scans.
Gadoterate meglumine is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is an injectable solution that enhances the visibility of internal body structures during MRI scans.
The MAGNETOM Skyra is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for various medical applications. The MAGNETOM Skyra utilizes advanced technology to generate detailed images of the body's internal structures without the use of ionizing radiation.
Sourced in Netherlands, Germany, United States, Switzerland, Japan
The Philips Ingenia is a magnetic resonance imaging (MRI) system designed for diagnostic imaging. It provides high-quality images of the body's internal structures to aid in the detection and diagnosis of various medical conditions.
The Magnetom Avanto is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for a variety of clinical applications. The Magnetom Avanto utilizes a strong magnetic field and radio waves to generate detailed images of the body's internal structures.
Sourced in Netherlands, Germany, United States, United Kingdom, Japan
The Philips Achieva is a versatile laboratory equipment designed for a range of analytical and research applications. It offers advanced capabilities for tasks such as sample preparation, separation, and detection. The Achieva is engineered to provide reliable and consistent performance, making it a valuable tool for various scientific disciplines.
Sourced in United States, Ireland, United Kingdom, Germany, China, Norway, France
Omniscan is a contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visibility of certain structures or abnormalities within the body during the imaging process. Omniscan is administered intravenously prior to the MRI scan.
Sourced in Germany, United States, Japan, Canada, Switzerland, United Kingdom, France, Spain
Gadovist is a contrast agent used in magnetic resonance imaging (MRI) procedures. It contains the active ingredient gadobutrol, which enhances the visibility of certain structures within the body during the MRI scan.
Sourced in Germany, United States, Japan, China, United Kingdom, Jersey, Canada, Ireland
Magnevist is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures and improve the diagnostic capabilities of MRI scans.
The Magnetom Aera is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality, diagnostic-grade imaging data. The Magnetom Aera utilizes a powerful superconducting magnet and advanced imaging technologies to capture detailed images of the human body's internal structures and functions.
Gadoterate meglumine is a specific paramagnetic contrast agent and does not have different types or variations. It is a single compound composed of the rare earth metal gadolinium chelated with the organic ligand meglumine.
Gadoterate meglumine is commonly used in magnetic resonance imaging (MRI) procedures to enhance the visualization of internal body structures. It is often used to detect and evaluate a variety of conditions, including brain and spinal cord lesions, tumors, and vascular abnormalities. The contrast agent helps increase the contrast between different tissues, allowing for better identification and assessment of these medical issues.
PubCompare.ai's AI-driven platform can assist researchers in optimizing the use of Gadoterate meglumine in several ways: 1. Screeing protocol literature more efficiently: The platform can help researchers quickly identify and access relevant protocols from literature, preprints, and patents related to the use of Gadoterate meglumine. 2. Leveraging AI to pinpoint Critical Insights: PubCompare.ai's AI-driven analysis can highlight key differences in protocol effectiveness, enabling researchers to choose the best options for improving reproducibility and accuracy in their Gadoterate meglumine-related studies. 3. Identifying the most effective protocols: The platform's powerful tools can help researchers locate and compare the best protocols from various sources, ensuring they select the most effective approaches for their specific research goals involving Gadoterate meglumine.
One of the main challenges with using Gadoterate meglumine is ensuring proper dosage and administration. It is important to follow the manufacturer's instructions and consult with medical professionals to determine the appropriate dosage and administration method for each patient or research application. Additionally, researchers must be mindful of potential side effects, such as nephrogenic systemic fibrosis, and take the necessary precautions when using Gadoterate meglumine.
PubCompare.ai's AI-driven platfrom can help researchers improve the reproducibility and accuracy of their Gadoterate meglumine research in several ways. By allowing researchers to quickly screen protocol literature and leveraging AI to identify the most effective protocols, the platform enables researchers to choose the best options for their specific research goals. This helps enhance the reproducibility of their studies and improves the overall accuracy of their findings related to the use of Gadoterate meglumine.
More about "Gadoterate meglumine"
Gadoterate meglumine is a paramagnetic contrast agent used in magnetic resonance imaging (MRI) procedures.
It is a chelate of the rare earth metal gadolinium and the organic ligand meglumine.
Gadoterate meglumine, also known as Dotarem, enhances the visualization of internal body structures by increasing the contrast between different tissues.
It is commonly used to detect and evaluate a variety of conditions, including brain and spinal cord lesions, tumors, and vascular abnormalities.
The use of gadoterate meglumine in MRI scans can be optimized through the use of advanced imaging technologies like MAGNETOM Skyra, Ingenia, Magnetom Avanto, Achieva, and Magnetom Aera.
These state-of-the-art MRI systems, developed by leading manufacturers like Siemens, can provide high-quality images and improve the accuracy of diagnoses.
In addition to gadoterate meglumine, other gadolinium-based contrast agents like Omniscan and Gadovist are also used in MRI procedures.
These agents can help enhance the visualization of various anatomical structures and pathologies, aiding in the early detection and management of a wide range of medical conditions.
Experieince the power of optimized research protocols with PubCompare.ai's AI-driven platform, which can help you locate and compare the best protocols from literature, preprints, and patents to improve the reproducibility and accuracy of your Gadoterate meglumine research.
Discover how PubCompare.ai's innovative tools can enhance the future of your MRI-based studies and diagnostics.
